RT Journal Article
SR Electronic
T1 Utility of PET/CT in the prediction of response and disease-free survival in locally advanced esophageal cancer
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 1311
OP 1311
VO 53
IS supplement 1
A1 Robles Barba, Javier
A1 Galán Guzmán, Maica
A1 Font Pous, Albert
A1 Cortes Romera, Montserrat
A1 Rodriguez Bel, Laura
A1 Rossi Seoane, Susana
A1 Caresia Aroztegui, Ana Paula
A1 Bettonica Larranaga, Carla
A1 Boladeras Inglada, Ana María
A1 Gamez Cenzano, Cristina
YR 2012
UL http://jnm.snmjournals.org/content/53/supplement_1/1311.abstract
AB 1311 Objectives To evaluate the utility of FDG-PET/CT in the assessment of neoadjuvant therapy response and prediction of disease-free survival in patients with locally advanced esophageal cancer. Methods Thirty-six patients with locally advanced esophageal cancer (23 squamous cell, 13 adenocarcinoma) treated with neoadjuvant chemoradiotherapy and surgery were included in the study. All patients underwent FDG-PET/CT scans 4 weeks before and after neoadjuvant therapy and were classified in 3 groups based on the decrease of SUVmax between the two PET/CT scans performed. Group 1: Non-significant response (decrease <50%). Group 2: Partial response (decrease >50%). Group 3: Complete response. It was evaluated whether decrease of SUVmax could predict histopathologic response to treatment and Free Recurrence Interval (FRI). Reference standards for treatment response and recurrence were histopathology results. Results Four patients were excluded due to absence of FDG uptake in the staging PET-CT and two due to dead related to post-surgery complications. Attending to metabolic response, groups 1, 2 and 3 included 4, 22 and 5 patients respectively. Recurrence was detected in 50% of patients of group 1 (avFRI: 13 months), 50% of group 2 (avFRI: 16 m) and 25% of group 3 (avFRI: 25 m). Independent analysis of adenocarcinoma and squamous cell, showed the same recurrence rate (50% en both groups) and very similar avFRI (15 and 17 months respectively). Conclusions Decrease of SUVmax after neoadjuvant therapy evaluated by PET/CT in locally advanced esophageal cancer seems to be a predicting factor of treatment response and disease-free survival. In our study, patients with adenocarcinoma showed worse metabolic response to neoadjuvant therapy than squamous cell patients, but similar avFRI and recurrence rate